Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05089747

CIRculating CANcer MAster-Protocol

This exploratory study will focus on the development of the analyses of blood biomarkers to better understand the circulating biomarkers associated with cancer diagnosis, treatment efficacy and progressive disease

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Adult With Solid Cancer

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Service de Pneumologie Hôpital Louis Pradel / Groupement Hospitalier Est, Bron, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult (>18y)
  • Owing a social security insurance
  • Any solid cancer diagnosed by histopathology or cytology
  • Patient with blood sampling required as per standard of care
  • Informed consent signed

Exclusion criteria

  • Refusal to participate
  • No blood sampling required as per standard of care
  • Hemoglobin < 7g/dl (< 9g/dl if respiratory or cardiovascular disease history)
  • Heterologous blood transfusion in the last 48 hours
  • Weight under 20 kg

Treatment and study plan

Blood sampling for biomarker analysis (microRNA, circulating DNA…)

Biological

From one to four blood samplings: at diagnosis, after the first cycle of treatment, end of treatment, progressive disease (or end of study).

Primary outcomes

  1. Liquid biopsy analyses

    Time frame: Day 0

    Extraction of circulating DNA or circulating RNA followed by a tumoral cells extraction.

  2. Standard technics of disease assessment

    Time frame: Week 16

    Genetic and transcriptomic explorations with immunofluorescence technique. Marking with specific markers of the tumor pathology. And enumaration of tumoral cells.

  3. Correlation between outcome 1 and outcome 2

    Time frame: year 5

    Building a biological collection of blood samples and following, diagnosis and prediction of adult solid cancer.

Study contacts

Contact information is provided by the study sponsor or research team.

Sebastian Couraud, MD, PhD

CONTACT

[email protected]

+33 4 478 864 401

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Official study title

MAster Protocol Studying the Impact of Blood Biopsy on Screening, Diagnosis, Diagnostic and Follow-up of Solid Cancer in Adult

Acronym: CIRCAN MAP

Important dates

Study start
2022
Primary completion
2047
Study completion
2047
First posted
Oct 22, 2021
Registry last updated
Jun 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.